Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review

Breast Cancer Research and Treatment

Volumn 147, Issue 2, 2014, Pages 237-248

  Ioannides, S J ^a   Barlow, P L ^b   Elwood, J M ^a   Porter, D ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Anastrozole; Aromatase inhibitor; Breast cancer; Drug therapy; Exemestane; Letrozole; Obesity; Treatment

Indexed keywords

AROMATASE INHIBITOR;

BREAST NEOPLASMS; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; METABOLISM; NEOPLASM RECURRENCE, LOCAL; OBESITY; OBSERVATIONAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OBESITY; OBSERVATIONAL STUDY AS TOPIC; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84930011936     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3091-7     Document Type: Review

References (39)

1. Bagchi D, Preuss H (2013) Obesity: epidemiology, pathophysiology, and prevention, vol 2nd. CRC Press, New York
2. Niraula S, Ocana A, Ennis M et al (2012) Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat 134:769–781
3. National Health Institute. Obesity and cancer risk. secondary obesity and cancer risk. http://www.cancer.gov/cancertopics/factsheet/Risk/obesity. Accessed 18 July 2014
4. GLOBOCAN (2012) GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Secondary GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 18 July 2014
5. Sanford M, Plosker GL (2008) Anastrozole. Drugs 68(9):1319–1340. doi:10.2165/00003495-200868090-00007
6. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431–2442
7. Morris PG, Hudis CA, Giri D et al (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 4(7):1021–1029
8. Subbaramaiah K, Howe LR, Bhardwaj P et al (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 4(3):329–346
9. Goodwin PJ, Pritchard KI (2010) Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol 28(21):3405–3407
10. Wolters R, Schwentner L, Regierer A et al (2012) Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle. Breast Cancer Res Treat 131(3):925–931
11. Moher D, Liberati A, Tetzlaff J, et al, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed.1000097
12. Ewertz M, Gray KP, Regan MM et al (2012) Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30(32):3967–3975
13. Gnant M, Pfeiler G, Stoger H et al (2013) The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer 109(3):589–596
14. Sendur MAN, Aksoy S, Zengin N et al (2012) Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. Br J Cancer 107(11):1815–1819
15. Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411–3415
16. Sahin U, Petekkaya I, Arslan C et al (2012) Impact of obesity in postmenopausal early breast cancer patients receiving frontline adjuvant aromatase inhibitors. J Clin Oncol 30(suppl):e11020
17. Michaud LB, Buzdar AU, Rubin S et al (2002) The efficacy of anastrozole is not dependent upon body mass index (BMI) in postmenopausal women with advanced breast cancer (BC). Proc Am Soc Clin Oncol 21:55a
18. Schmid P, Possinger K, Bohm R et al (2000) Body mass index as predictive parameter for response and time to progression (TTP) in advanced breast cancer patients treated with letrozole or Megestrol Acetate. Proc Am Soc Clin Oncol 19:103a
19. Michaud LB, Buzdar AU (1999) Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 27(4):297–309
20. Cuzick J, Sestak I, Baum M et al (2011) 10-year analysis of the ATAC trial: wrong conclusion?—Authors’ reply. lancet 12:201–312
21. Jakesz R, Greil R, Gnant M (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast and colorectal cancer study group trial 6a. J Natl Cancer Inst 99:11845–11853
22. Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 12(12):1101–1108. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/418/CN-00804418/frame.html. Accessed 18 July 2014
23. Goss PE (2006) Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin Oncol 33(2 Suppl 7):S8–12 doi:10.1053/j.seminoncol.2006.03.025
24. Mamounas EP, Jeong JH, Wickerham DL et al (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 26(12):1965–1971. doi:10.1200/jco.2007.14.0228
25. Pfeiler G, Konigsberg R, Fesl C et al (2011) Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 29(19):2653–2659
26. Folkerd E, Dixon J, Renshaw L et al (2012) Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol 30(24):2977–2980
27. Kittaneh M, Gluck S (2011) Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer 5:209–226. doi:10.4137/BCBCR.S6234
28. Geisler J, Haynes B, Anker G et al (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20(3):751–757
29. Gershanovich M, Chaudri HA, Campos D et al (1998) Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9:639–645
30. Gnant M, Mlineritsch B, Stoeger H et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7):631–641
31. Bhatnagar AS, Brodie AMH, Long BJ et al (2001) Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem and Mol Biol 76(1–5):199–202. doi:10.1016/S0960-0760(01)00050-4
32. Miller W (2008) Background and development of aromatase inhibitors. In: BJA F (ed) Milestones in drug therapy, aromatase inhibitiors, 2nd edn. pp 1–21
33. Dowsett M, Coombes RC (1994) Second generation aromatase inhibitor—4-hydroxyandrostenedione. Breast Cancer Res Treat 30(1):81–87. doi:10.1007/BF00682742
34. Dixon JM, Renshaw L, Young O et al (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26(10):1671–1676. doi:10.1200/JCO.2007.13.9279
35. Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39(16):2318–2327
36. World Health Organization. BMI classification. Secondary BMI classification. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed 18 July 2014
37. Jonat W, Howell A, Blomqvist C et al (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A(3):404–412
38. Buzdar AU, Jones SE, Vogel CL et al (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. The Arimidex Study Group. Cancer 79:730–739. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/225/CN-00204225/frame.html. Accessed 18 July 2014
39. Ortega AF, Lopez LJ, Villaro GV et al (2011) Individualization of treatment strategies. Adv Ther 28(Suppl 6):19–38